Curanex Pharmaceuticals Inc

Research Curanex Pharmaceuticals Inc (CURX) on Bullrun: market cap USD 134.73M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 134.73M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 4.23M-USD 10.48Mn/a-0.17USD 5.00MUSD 346.70KUSD 11.22M
FY2024n/a-USD 361.51Kn/an/a-0.03USD 148.89KUSD 0USD 503.36K

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 134.73Mn/an/an/a
20252025-12-31USD 9.35Mn/an/an/a

About Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Curanex Pharmaceuticals Inc's market cap?

Curanex Pharmaceuticals Inc's market capitalization is USD 134.73M.

What does Curanex Pharmaceuticals Inc do?

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.